Sun Pharmaceutical Industries Limited (SUNPHARMA)
Press Release for lerodalcibep licensing agreement
Sun Pharma entered exclusive licensing, commercialization, and manufacturing agreement for lerodalcibep outside US and China. Lerodalcibep (Lyrokaul) approved in EU on Sep 21, 2026, for LDL-C lowering in adults with hypercholesterolemia. The global PCSK9 market excluding US and China is $3.7bn, growing at 38% CAGR. Sun Pharma will pursue regulatory approvals in licensed territories. LIB Therapeutics to receive upfront, milestone payments, and royalties.
Source: Original filing PDF
—
view on exchange portal
⚡ You're reading this after the fact — subscribers got it instantly
ISA
Indian Stock Alerts
BOT
🚨 SUNPHARMA — Quarterly Results
Revenue: ₹2,35,800 Cr (+12% YoY)
PAT: ₹19,200 Cr (+17% YoY)
EBITDA margin: 16.8%
Board declared ₹10/share dividend. Jio adds 8M subs.
📎 bseindia.com/xml-data/...
🎧 Audio summary ready
✓✓ 6:47 PM
Instant audio summaries2-min AI concall recap delivered with every earnings alert
20-quarter financialsRevenue, PAT, EBITDA, margins — auto-extracted from filings
Forensic red-flag screenAudit, governance, accruals & RPT flags scored automatically
Instant Telegram alertsResults, board meetings, insider trades — within minutes
Add SUNPHARMA to your watchlist — all of this, automated.
Sign in with Google14-day Pro trial · No credit card · Cancel anytime
More on Sun Pharmaceutical Industries Limited
Important.
The summary above is generated automatically from Sun Pharmaceutical Industries Limited's own
public regulatory filing under SEBI LODR. Indian Stock Alerts is
not a SEBI-registered Research Analyst or Investment Adviser.
This page is informational, not investment advice, a recommendation to buy
or sell any security, or any opinion about the company's business, governance
or financial health. Always read the original filing before acting and consult
a registered adviser for investment decisions.